SalivIQ reports $1.9M sold in seed round, with $1.26M left
SalivIQ founder Julia Halterman is building a saliva-based strep test; a September SEC filing reports $707,000 more sold since June and a larger offering target.
By RuntimeWire Staff · Published
Primary source: U.S. Securities and Exchange Commission
Why it matters
SalivIQ's amendment reveals that its seed offering has grown well beyond the amount reported in June, while the product still has to translate a 102-sample research result into a cleared and repeatable clinical test.
SalivIQ Diagnostics founder and CEO Julia Halterman is named in a September 23rd SEC filing reporting that SalivIQ had sold $1,911,999 in its seed offering. The filing lists 50 investors and an offering target of $3.17 million, leaving $1,258,001 under that target.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.